GERUSSI, ALESSIO
 Distribuzione geografica
Continente #
NA - Nord America 8.064
EU - Europa 6.569
AS - Asia 6.485
SA - Sud America 963
AF - Africa 173
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 22.263
Nazione #
US - Stati Uniti d'America 7.669
SE - Svezia 2.385
SG - Singapore 2.125
VN - Vietnam 1.415
IT - Italia 1.288
CN - Cina 1.076
HK - Hong Kong 877
RU - Federazione Russa 734
BR - Brasile 716
DE - Germania 699
IE - Irlanda 344
CA - Canada 306
GB - Regno Unito 280
FR - Francia 207
IN - India 200
KR - Corea 129
FI - Finlandia 113
BD - Bangladesh 105
ID - Indonesia 102
AR - Argentina 96
NL - Olanda 90
IQ - Iraq 68
AT - Austria 64
ZA - Sudafrica 64
ES - Italia 63
PL - Polonia 59
TR - Turchia 56
CH - Svizzera 52
MX - Messico 49
SA - Arabia Saudita 41
UA - Ucraina 41
PH - Filippine 39
MY - Malesia 38
EC - Ecuador 34
PK - Pakistan 33
CO - Colombia 29
JP - Giappone 28
VE - Venezuela 27
BE - Belgio 26
DK - Danimarca 26
LT - Lituania 24
UZ - Uzbekistan 24
IL - Israele 21
MA - Marocco 19
CL - Cile 15
KE - Kenya 15
TN - Tunisia 14
CZ - Repubblica Ceca 13
PY - Paraguay 13
BO - Bolivia 12
EG - Egitto 12
JO - Giordania 12
AZ - Azerbaigian 11
ET - Etiopia 10
IR - Iran 10
JM - Giamaica 10
KZ - Kazakistan 10
AE - Emirati Arabi Uniti 9
DZ - Algeria 9
SK - Slovacchia (Repubblica Slovacca) 9
UY - Uruguay 9
CR - Costa Rica 7
GR - Grecia 7
PE - Perù 7
PT - Portogallo 7
RS - Serbia 7
TW - Taiwan 7
AU - Australia 6
NP - Nepal 6
PA - Panama 6
HU - Ungheria 5
MM - Myanmar 5
RO - Romania 5
SY - Repubblica araba siriana 5
AO - Angola 4
CI - Costa d'Avorio 4
DO - Repubblica Dominicana 4
MD - Moldavia 4
PS - Palestinian Territory 4
QA - Qatar 4
TH - Thailandia 4
AL - Albania 3
CG - Congo 3
GE - Georgia 3
GY - Guiana 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
MU - Mauritius 3
NO - Norvegia 3
SC - Seychelles 3
TT - Trinidad e Tobago 3
BG - Bulgaria 2
GH - Ghana 2
HN - Honduras 2
KH - Cambogia 2
LU - Lussemburgo 2
LY - Libia 2
MR - Mauritania 2
NG - Nigeria 2
Totale 22.231
Città #
Stockholm 1.879
Singapore 1.290
Ann Arbor 1.272
Hong Kong 845
Ashburn 695
San Jose 659
Frankfurt am Main 521
Ho Chi Minh City 432
Milan 427
Fairfield 361
Hanoi 359
Dublin 328
Chandler 292
Dallas 279
Wilmington 270
Chicago 257
Toronto 250
Los Angeles 236
New York 232
Hefei 221
Santa Clara 215
Woodbridge 167
The Dalles 153
Houston 144
Seattle 143
Beijing 129
Seoul 123
Cambridge 119
London 117
Lauterbourg 102
Princeton 98
Jakarta 78
Buffalo 76
Shanghai 75
Helsinki 74
São Paulo 72
Council Bluffs 70
Moscow 70
Rome 68
Dearborn 66
Munich 62
Orem 49
Boardman 48
Zurich 47
Altamura 46
Lawrence 46
Haiphong 41
Warsaw 41
Da Nang 40
Monza 37
Biên Hòa 35
Johannesburg 33
Ha Long 30
Turin 30
Florence 29
Nuremberg 29
Vienna 29
Rio de Janeiro 28
San Diego 28
Atlanta 26
Hải Dương 26
Pune 25
Denver 24
Tokyo 24
Can Tho 23
Quận Bình Thạnh 23
Baghdad 22
Montreal 22
New Delhi 22
Turku 22
Brussels 21
Jacksonville 21
Mumbai 21
Ninh Bình 21
Amsterdam 20
Guangzhou 20
Riyadh 20
Salt Lake City 20
Chennai 19
Tashkent 19
Belo Horizonte 18
Boston 17
Brooklyn 17
Lappeenranta 17
Bari 16
Bắc Ninh 16
Penang 16
Poplar 16
Dhaka 15
Phoenix 15
Vũng Tàu 15
Istanbul 14
Nanjing 14
Naples 14
Paris 14
Quận Một 14
Tampa 14
Thái Nguyên 13
Brasília 12
Curitiba 12
Totale 14.752
Nome #
Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial 1.945
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 581
Gamma-Glutamyl Transferase in Patients With Primary Biliary Cholangitis 450
Quality of life in patients with primary biliary cholangitis: a cross-geographical comparison 405
A second update on mapping the human genetic architecture of COVID-19 362
Mapping the human genetic architecture of COVID-19 338
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 335
Risk stratification in primary sclerosing cholangitis 331
Accuracy of Liver Stiffness Measurement in assessing liver fibrosis in naïve patients with Primary Biliary Cholangitis 330
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 329
Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms 328
Precision medicine in primary biliary cholangitis 323
FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study 314
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach 312
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 311
A NOVEL MACHINE-LEARNING, COMMON VARIANTS-BASED APPROACH TO PREDICT PRIMARY BILIARY CHOLANGITIS 292
FRI-006-Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis 290
Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group 286
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 283
New Therapeutic Targets in Autoimmune Cholangiopathies 282
Better end points needed in primary sclerosing cholangitis trials 280
THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis 276
Machine learning in primary biliary cholangitis: A novel approach for risk stratification 271
Immune-mediated drug-induced liver injury: Immunogenetics and experimental models 263
Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis 259
Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 253
Artificial Intelligence and liver: Opportunities and barriers 251
Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies 249
Case Report: Hypomorphic Function and Somatic Reversion in DOCK8 Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis 249
Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma 248
Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets 247
DISSECTING THE GENETIC ARCHITECTURE OF AUTOIMMUNITY: A SPOTLIGHT ON PRIMARY BILIARY CHOLANGITIS 240
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 239
FRI-011-Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 231
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 229
Artificial intelligence for precision medicine in autoimmune liver disease 227
Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markers 226
Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe 225
Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis 225
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 225
Deep learning helps discriminate between autoimmune hepatitis and primary biliary cholangitis 224
A National Hospital‐Based Study of Hospitalized Patients With Primary Biliary Cholangitis 224
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) 224
Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study 223
Improving predictive accuracy in primary biliary cholangitis: A new genetic risk score 222
Novel insights in primary biliary cholangitis (PBC) epidemiology using administrative records 222
Established cirrhosis at the time of diagnosis predicts adverse outcome in autoimmune hepatitis: A retrospective cohort study 213
Role of ductular reaction and ductular–canalicular junctions in identifying severe primary biliary cholangitis 212
Stratified analyses refine association between TLR7 rare variants and severe COVID-19 211
X marks the spot in autoimmunity 204
Primary sclerosing cholangitis: Burden of disease and mortality using data from the national rare diseases registry in Italy 202
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 197
Corrigendum to: “An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs” [J Hepatol 75 (2021) 572-581, (S0168827821003342), (10.1016/j.jhep.2021.04.055)] 197
The immunobiology of female predominance in primary biliary cholangitis 197
Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis 197
Association Between Black Race and Presentation and Liver-Related Outcomes of Patients With Autoimmune Hepatitis 194
The Role of Macrophages in Liver Fibrosis: New Therapeutic Opportunities 189
The phenotypic landscape of primary biliary cholangitis and autoimmune hepatitis variants 186
Cost of illness of Primary Biliary Cholangitis - a population-based study 183
Open challenges in the management of autoimmune hepatitis 174
New insights on the role of human leukocyte antigen complex in primary biliary cholangitis 174
Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis 174
LLM-PBC: Logic Learning Machine-Based Explainable Rules Accurately Stratify the Genetic Risk of Primary Biliary Cholangitis 172
The application of artificial intelligence in hepatology: A systematic review 167
The Role of Epigenetics in Primary Biliary Cholangitis 162
Gender differences in liver disease and the drug-dose gender gap 159
The role of ethnicity in autoimmune hepatitis 156
Normalization of serum immunoglobulin G levels is associated with improved transplant-free survival in patients with autoimmune hepatitis 153
Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis 145
Bacterascites confers poor patient prognosis beyond MELD prediction 143
EFFICACY OF OBETICHOLIC ACID IN PRIMARY BILIARY CHOLANGITIS-AUTOIMMUNE HEPATITIS OVERLAP PATIENTS WITH PERSISTENTLY ELEVATED TRANSAMINASES DESPITE IMMUNOSUPPRESSION 143
The prognosis following bacterascites is as poor as spontaneous bacterial peritonitis 142
Identifying Racial Disparities in Primary Biliary Cholangitis Patients: A Step Toward Achieving Equitable Outcomes Among All 139
MEDTEC students against coronavirus: Investigating the role of hemostatic genes in the predisposition to COVID-19 severity 139
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group 132
Pre-treatment risk stratification in primary biliary cholangitis: A predictive model to guide first-line combination therapy 129
Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase 128
Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on the alkaline phosphatase 126
GWAS and autoimmunity: What have we learned and what next 125
Elevated baseline igg is a risk factor for on-treatment flares of autoimmune hepatitis in patients in biochemical remission 123
Diagnostic Yield of Whole Exome Sequencing in Adult-onset Cholestatic Liver Disease 122
SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis 121
Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis 121
ANTITUMOR ACTIVITY OF A NOVEL FGFR INHIBITOR IN INTRAHEPATIC CHOLANGIOCARCINOMA 113
Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis 112
Automating liver biopsy segmentation with a robust, open-source tool for pathology research: the HOTSPoT model 111
Primary Sclerosing Cholangitis 110
Genetics of Primary Biliary Cholangitis 109
Genetics of Autoimmune Liver Diseases 108
Anti-gp210 and other anti-nuclear pore complex autoantibodies in primary biliary cholangitis: What we know and what we should know 103
Cluster analysis reveals the prognostic role of serum albumin within the normal range in patients with primary biliary cholangitis 97
The genetic architecture of primary biliary cholangitis 97
Editorial: liver transplantation for primary biliary cholangitis–the need for timely and more effective treatments 96
Black Ethnicity Affects the Clinical Presentation and Outcome in Autoimmune Hepatitis 95
Association between black race and presentation and liver-related outcomes of patients with autoimmune hepatitis 85
Diagnosing Autoimmune Hepatitis: Histological Correlations and Emerging Technologies 79
EVALUATION OF PROGNOSTIC FACTORS OF OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) 79
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis 75
NON ADHERENCE TO AASLD - EASL GUIDELINES FOR THE MANAGEMENT OF HEPATOCELLULAR CARCINOMA DOES NOT TRANSLATE INTO WORSE OUTCOMES 74
Primary Biliary Cholangitis 71
Totale 22.344
Categoria #
all - tutte 72.568
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.568


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021213 0 0 0 0 0 0 0 0 0 0 119 94
2021/20221.051 107 104 160 108 79 61 43 69 48 25 85 162
2022/20231.850 172 440 148 141 236 245 86 90 112 64 70 46
2023/20241.644 49 59 75 161 187 328 207 37 76 172 40 253
2024/20253.885 254 400 218 187 325 197 247 209 426 532 361 529
2025/202611.680 1.536 827 807 1.113 954 499 1.422 519 797 2.715 491 0
Totale 22.802